Novacyt sees good sales growth amid working capital challenges

Clinical diagnostics company Novacyt updated the market on its trading for the six months ended 30 June on Tuesday, reporting that its unaudited revenues in the first half were €7.2m. The AIM-traded firm said that compared well to the restated revenues for 2018 of €6.4m, with strong growth seen from its molecular diagnostics business ‘Primerdesign’. Continuing group revenue excluding ��NOVAprep’ increased by 12%, or 11% at constant exchange rates, with peak sales of €1.4m for the month of June at a group level. NOVAprep revenues were excluded to reflect the strategic decision to sell the division, as the company announced on 11 December, which remained an ongoing process.